Found 1 Presentation For Request "130p"
130P - PTCH1 Genomic Alterations (GA) in human malignancies: A pangenomic study
- Jeffrey S. Ross (Albany, NY, United States of America)
Abstract
Background
Vismodegib and sonidegib are FDA approved for treatment of advanced basal cell carcinoma (BCC), but only 30-40% of patients (pts) respond to these drugs. Inactivating GA in the
Methods
297,209 consecutive clinically advanced cases of malignancy were submitted for comprehensive genomic profiling (CGP) using a hybrid capture based assay. Tumor mutational burden (TMB) and microsatellite instability (MSI) were determined as described (PMID:
Results
Overall, 3,047 (1.0%) sequenced cases featured
Conclusions
Although highly associated with skin BCC,
Legal entity responsible for the study
Foundation Medicine Inc.
Funding
Foundation Medicine Inc.
Disclosure
J.S. Ross: Leadership role, Research grant/Funding (self), Shareholder/Stockholder/Stock options, Full/Part-time employment: Foundation Medicine Inc.; Advisory/Consultancy: Celsius Therapeutics. E.S. Sokol: Shareholder/Stockholder/Stock options, Full/Part-time employment: Foundation Medicine Inc. D.C. Pavlick: Full/Part-time employment: Foundation Medicine Inc. J-A. Vergilio: Shareholder/Stockholder/Stock options, Full/Part-time employment: Foundation Medicine Inc. J.K. Killian: Shareholder/Stockholder/Stock options, Full/Part-time employment: Foundation Medicine Inc. E. Williams: Shareholder/Stockholder/Stock options, Full/Part-time employment: Foundation Medicine Inc. N.A. Danziger: Full/Part-time employment: Foundation Medicine Inc. J. Tse: Full/Part-time employment: Foundation Medicine Inc. S. Ramkissoon: Shareholder/Stockholder/Stock options, Full/Part-time employment: Foundation Medicine Inc. E. Severson: Shareholder/Stockholder/Stock options, Full/Part-time employment: Foundation Medicine Inc.; Full/Part-time employment: Partners Healthcare. A. Hemmerich: Shareholder/Stockholder/Stock options, Full/Part-time employment: Foundation Medicine Inc. D. Duncan: Shareholder/Stockholder/Stock options, Full/Part-time employment: Foundation Medicine Inc. R. Huang: Shareholder/Stockholder/Stock options, Full/Part-time employment: Foundation Medicine Inc.; Licensing/Royalties, IHC patent: Roche/Ventana. R. Madison: Shareholder/Stockholder/Stock options, Full/Part-time employment: Foundation Medicine Inc. A.B. Schrock: Shareholder/Stockholder/Stock options, Full/Part-time employment: Foundation Medicine Inc. B. Alexander: Leadership role, Full/Part-time employment: Foundation Medicine Inc.; Research grant/Funding (institution): Celgene; Research grant/Funding (institution): Puma; Research grant/Funding (institution): Eli Lilly. J. Venstrom: Shareholder/Stockholder/Stock options, Full/Part-time employment: Foundation Medicine Inc.; Full/Part-time employment: Genentech. P. Reddy: Travel/Accommodation/Expenses, Shareholder/Stockholder/Stock options, Full/Part-time employment: Foundation Medicine Inc. K. McGregor: Shareholder/Stockholder/Stock options, Full/Part-time employment: Foundation Medicine Inc. J. Elvin: Shareholder/Stockholder/Stock options, Full/Part-time employment: Foundation Medicine Inc..